Phibro Animal Health stock price target raised to $37 by BNP Paribas

Phibro Animal Health Corp. (PAHC) reported stronger-than-expected Q4 results and robust FY2026 guidance, prompting BNP Paribas Exane to significantly raise its price target to $37.00 from $24.00, while maintaining a Neutral rating. This reflects PAHC's strong revenue growth, margin expansion, and key drivers such as the Zoetis MFA integration and completed customer destocking, which have contributed to an 84.3% year-to-date stock surge. Despite the positive outlook and increased EPS estimates, BNP Paribas suggests the stock's current 12.8x EV/EBITDA valuation fairly reflects its prospects, aligning with InvestingPro's assessment that it trades above its fair value.

Analysis

Phibro Animal Health Corp. (PAHC) has demonstrated significant operational and stock market momentum, prompting a price target increase from BNP Paribas Exane to $37.00 from $24.00, though the firm maintains a Neutral rating. The positive revision is underpinned by a strong fourth-quarter 2025 performance, where EPS of $0.57 beat estimates by 9.62% and revenue of $378.7 million surpassed forecasts. This performance is supported by robust fundamentals, including a 27.37% year-over-year revenue growth and a strong liquidity position indicated by a current ratio of 2.76. Key growth catalysts include the successful integration of the Zoetis MFA portfolio without cannibalization and the conclusion of customer destocking, paving the way for cleaner growth in fiscal year 2026. However, despite the strong outlook and a 16% increase in FY26/27 EPS estimates by BNP, valuation is a point of caution. The stock, having surged 84.3% year-to-date, currently trades at an EV/EBITDA multiple of 12.8x. This level is considered to fairly reflect its prospects by BNP and is noted as trading above its fair value by InvestingPro, justifying the Neutral stance despite the raised target multiple of 9.5x for FY26, which remains at a notable 30% discount to competitor Elanco.

Key Decisions for Investors

• Given the stock's 84.3% year-to-date appreciation and the analyst consensus that it is now fairly valued, investors should be cautious about initiating new positions as the positive outlook appears largely priced in.
• Existing shareholders with significant gains may consider trimming their positions to realize profits, aligning with the Neutral rating that suggests limited further upside from current levels.
• Monitor the company's ability to sustain its high gross margins and achieve projected growth, as any failure to meet the elevated expectations embedded in the current 12.8x EV/EBITDA multiple could trigger a valuation correction.